Incretins

GLP-1 and DPP-4 inhibitors

Incretins are hormones produced in the gut. These include glucagon-like peptide 1 (GLP 1) and glucose-dependent insulinotropic polypeptide (also gastric inhibitory polypeptide, gastric inhibitor polypeptide; GIP). Their production is stimulated by food intake. They were first isolated from the saliva of a poison ivy lizard.

Among other things, incretins increase the sensitivity of pancreatic β-cells to secretory stimuli and decrease glucagon secretion, thereby reducing hepatocyte glucose output. Therefore, dipeptidyl peptidase 4Template: HVLP (DPP-4) inhibitors and GLP-1 agonists are used to treat type 2 diabetes mellitus - Template: HVLP, Template: HVLP and others = incretin analogues.

Resources

• Oral antidiabetics
• Diabetes mellitus - type 2
• Incretin analogues

References

KVAPIL, Milan – ANDĚL, Michal. Terapeutické využití inkretinů : Doporučení ČDS [online]. Česká diabetologická společnost, ©2008. The last revision 2008-04-01, [cit. 2011-03-06]. <http://www.diab.cz/dokumenty/inkretiny_08.pdf>.

DRUCKER, Daniel J – NAUCK, Michael A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet [online]. 2006, y. 368, no. 9548, p. 1696-705, Available from <https://www.ncbi.nlm.nih.gov/pubmed/17098089>. ISSN 0140-6736 (print), 1474-547X.